Dr. Michael Murray The IMMUNE FA CTOR - Natural MediFAQS
Dr. Michael Murray The IMMUNE FA CTOR - Natural MediFAQS
Dr. Michael Murray The IMMUNE FA CTOR - Natural MediFAQS
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
T H E I M M U N E F A C T O R<br />
natural medicines is to design studies where the<br />
outcome will surely be negative and then using the<br />
results to launch a media campaign that makes gross<br />
generalizations. In the last few years the media have<br />
reported several studies as showing “echinacea is not<br />
effective”, just as they have reported the<br />
“ineffectiveness” of other well known and trusted<br />
natural medicines. Of course, the real details of the<br />
studies were not given. Let’s examine one such<br />
questionable study. 28<br />
54<br />
A double blind, placebo-controlled study was conducted with 302<br />
volunteers from 4 military institutions and 1 industrial plant in<br />
Germany. <strong>The</strong> subjects were given either a placebo, or alcohol-based<br />
tinctures from either E. purpurea or E. angustifolia for twelve weeks.<br />
<strong>The</strong> main outcome measured was time until the first upper respiratory<br />
tract infection. Secondary outcome measures were the number of<br />
participants with at least one infection, global assessment, and<br />
adverse effects. <strong>The</strong> time until occurrence of the first upper respiratory<br />
tract infection was 66 days in the E. angustifolia group, 69 days in the<br />
E. purpurea group, and 65 days in the placebo group. In the placebo<br />
group, 36.7 percent had an infection while in the E. angustifolia it was<br />
32 percent and in the E. purpurea it was 29.3 percent. <strong>The</strong>se results<br />
seem to indicate that there was no real significant benefit with either<br />
form of echinacea although there was an approximately 20 percent<br />
reduced risk of infection in the echinacea groups. In addition,<br />
70 percent of the E. purpurea and 78 percent of the E. angustifolia<br />
group felt they had benefited from treatment compared to 56 percent<br />
in the placebo group. <strong>The</strong> E. angustifolia group had a slightly higher<br />
percentage of subjects experiencing side effects (18 percent)<br />
compared to the E. purpurea (10 percent) and placebo (11 percent)<br />
groups.